Yesterday, the CFO of Arrowhead Pharmaceuticals (ARWR – Research Report), Kenneth Allen Myszkowski, sold shares of ARWR for $1.06M. Following Kenneth Allen Myszkowski’s last ARWR Sell transaction on February 27, 2020, the stock climbed by 44.1%. In addition to Kenneth